Solti Innovative Breast Cancer Research
Research facility
Location:
Barcelona,
Spain (ES)
Identification of Patients with Early HR+ HER2- Breast Cancer at High Risk of Recurrence (2024)
Fasching P, Kreipe H, Del Mastro L, Ciruelos E, Freyer G, Korfel A, Chouaki N, et al.
Journal article, Review article
Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE) (2017)
Loibl S, De La Pena L, Nekljudova V, Zardavas D, Michiels S, Denkert C, Rezai M, et al.
Journal article